Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing By Investing.com

Exact Sciences Corp. (NASDAQ:), a leading provider of cancer screening and diagnostic tests, announced today that it will present 15 abstracts at the American Society of Clinical Oncology^® (ASCO^®) Annual Meeting 2023, June 2-6, in Chicago, Illinois. Presentations include new data confirming Exact Sciences’ approach to multi-cancer early detection (MCED), real-world outcomes using the Oncotype DX Breast Recurrence Score^®, and modeling comparisons between Cologuard^® and potential blood-based screening tests for colorectal cancer.^1-5

Long-term analyses from Detecting cancers Earlier Through Elective mutation-based blood Collection and Testing (DETECT-A), the first large, prospective, interventional study to screen for multiple cancers with a blood-based MCED test, showed that all patients diagnosed and treated for Stage I or II cancers remain cancer-free more than four years later. Most detected cancers had no standard of care screening tests. Data also showed that half of all patients with a cancer detected were successfully treated and remain cancer free more than four years after their initial test.^1-2 Earlier analyses showed that an MCED test more than doubled the number of screening-detected cancers compared to standard-of-care screening methods alone.⁶ These new, encouraging, long-term data outcomes in MCED-detected cancer survivors continue to provide important context for the advancements in the Exact Sciences MCED program.

“These first-ever, long-term MCED follow-up data confirm Exact Sciences’ approach to detecting multiple cancers at earlier stages of disease, and show that early detection enables successful treatment and long-term freedom from cancer in patients,” said Tom Beer, MD, Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences. “A vast majority of cancers have no screening option today, and an accurate screening method, capable of detecting multiple cancers, is key to decreasing the number of cancer deaths. We look forward to advancing our MCED program with new data presentations at future medical meetings throughout the rest of the year.”

In addition, Exact Sciences will present a new, long-term Surveillance, Epidemiology, and End Results (SEER) analysis showing that the Oncotype DX Breast Recurrence Score^® test is prognostic for breast cancer-specific mortality (BCSM) in…